Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Aflibercept
État du projet:
Terminé
Domaine thérapeutique:
Metastatic Colorectal Cancer
Fabricant:
Sanofi-aventis Canada Inc.
Brand Name:
Zaltrap
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0035-000
Strength:
25mg/mL
Tumour Type:
Gastrointestinal
Indications:
Metastatic Colorectal Cancer
Funding Request:
In combination with irinotecan-fluoropyrimidine (FOLFIRI) based therapy for patients with metastatic colorectal cancer previously treated with an oxaliplatin-containing regimen
Review Status:
Complete
Pre Noc Submission:
Yes
Date NOC Issued:
Sponsor:
Sanofi-aventis Canada Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Recommandation:
Ne pas rembourser
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016